4 completed, 2 terminated, 2 unknown, 1 not yet recruiting. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Unknown 2, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Serine: new trials by email Literature Review of Serine trials Research Report on Serine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Serine/Glycine-Restricted Diet, CAPOX Chemotherapy, PD-1 Inhibitor - Locally Advanced Rectal Cancer (LARC) | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 140 | 2026-08-31 | 2026-09-09 |
| Hereditary Sensory Neuropathy Serine Trial L-serine, Placebo - Hereditary Sensory Neuropathy Type I | Phase 2 | Unknown | University College, London | 50 | 2023-08-21 | 2023-11-02 |
| Serine and Fenofibrate Study in Patients With MacTel Type 2 Serine, Fenofibrate - Macular Telangiectasia Type 2 | Phase 2 | Completed | The Lowy Medical Research Institute Limited | 89 | 2022-04-07 | 2026-09-21 |
| Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) L-Serine - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Terminated | Elijah W. Stommel | 43 | 2018-10-24 | 2025-04-20 |
| Phase IIa L-serine Trial for eAD L-Serine, Placebo Gummy - Alzheimer Disease | Phase 2 | Terminated | Aleksandra Stark | 29 | 2017-03-01 | 2024-07-03 |
| L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 L-serine, placebo - Hereditary Sensory and Autonomic Neuropathy Type I | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 18 | 2013-09-01 | 2018-09-12 |
| Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet - Liver Cirrhosis | Phase 2 | Completed | Bausch Health Americas, Inc. | 420 | 2013-06-01 | 2019-10-23 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
| Determining the Safety of L-serine in ALS L-Serine - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Unknown | Phoenix Neurological Associates, LTD | 20 | 2013-01-01 | 2015-07-30 |
Amyotrophic Lateral Sclerosis (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Alzheimer Disease (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Liver Cirrhosis (1) · Pain (1)
Aleksandra Stark (1) · Bausch Health Americas, Inc. (1) · Elijah W. Stommel (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Massachusetts General Hospital (1) · Phoenix Neurological Associates, LTD (1) · The Lowy Medical Research Institute Limited (1) · University College, London (1) · Xuelei Ma MD (1)
United States (6) · United Kingdom (2) · China (1) · Russia (1) · Spain (1)
Aleksandra C Stark, MD (1) · Elijah W Stommel, MD,PHD (1) · Florian S Eichler, MD (1) · James Joffrion (1) · Jose Alegre-Martin, MD, PhD (1) · Mari A Gantner, PhD (1) · Todd D Levine, MD (1)
PMID 25386668, PMID 26212172, PMID 30626650, PMID 35750249, PMID 37467180, PMID 42231561, PMID 42660511